All Posts

Proposal to change funding criteria and supply arrangements for antiretroviral medicines used to treat HIV Pharmac is now consulting...

Coming up in CPD: Unlocking Options: Insulin Use in Type 2 Diabetes Management WEBINAR 14 October: Ryan Paul on the current role of...

Issue 330 - 2 October 2025 Welcome to the fortnightly Health Improvement and Innovation Digest. The Digest has links to key evidence of...

Proposal to change funding criteria and supply arrangements for antiretroviral medicines used to treat HIV Pharmac is now consulting...

We are writing to inform you of that there has been a delay with a recent shipment of Condyline solution 0.5%   Key messages: AFT...

Tender results Kia ora, Please find attached the 29 September 2025 Tender Notification . Ngā mihi,  Stefanie Moir | Tender Analyst Te...

The timeframe for developing Mental Health and Wellbeing Strategy has been extended to ensure alignment with proposed law changes Last...

Pharmac Update: Primary Care Prescribers | 26 September 2025   Below is the latest information on Pharmac consultations, notifications,...

Sunitinib: Brand change  The funded brand of 12.5 mg, 25 mg, and 50 mg sunitinib capsules is changing to Sunitinib Rex (Rex). There is a...

New listing: We are writing to inform you that from 1 October 2025 we are listing mesalazine 400mg tablets, Octasa brand.   This provides...

Making education easy Issue 34 - 2025 Please see the latest Child Health Research Review issue attached.

Proposal to fund medicines for multiple sclerosis, eye conditions, breast cancer and lung cancer Pharmac is seeking feedback on a...

Lemborexant for Insomnia Lemborexant (DAYVIGO) is a dual orexin receptor antagonist (DORA) used to treat insomnia in adults by helping...

Pharmac Update: Primary Care Prescribers | 19 September 2025   Below is the latest information on Pharmac consultations, notifications,...

New community medicine notices Ascorbic acid (Cvite) Tab 100 mg  (Pharmacode: 2642255) Supply of this product is limited. The next...

Issue 329 - 18 September 2025 Welcome to the fortnightly Health Improvement and Innovation Digest. The Digest has links to key evidence...

The Ministry of Health wants to hear your feedback on proposed amendments to the lists of specified prescription medicines and controlled drugs for designated registered nurse prescribers in primary health and specialty teams.   The current schedule of prescription medicines came into effect in August 2024. Since then, new medicines have become available in New Zealand, to which wider access would benefit patients. The schedule needs to be amended to reflect these additional

Proposed amendments to the specified prescription medicines lists under the Medicines ( Designated Pharmacist—Prescribers ) Regulations 2013   The Ministry of Health wants to hear your feedback on the proposed amendments to the specified prescription medicines list for designated pharmacist prescribers.   The current schedule of prescription medicines came into effect in May 2022. Since then, new medicines have become available in New Zealand, to which wider access would bene

Proposal to fund a new brand of methylphenidate for ADHD Pharmac is seeking feedback on a proposal to fund a new modified-release brand...